We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Discoveries of Prostate Cancer Evolution Pave Way for Genetic Test

By LabMedica International staff writers
Posted on 01 Mar 2024
Print article
Image: Prostate cancer cell image taken using a scanning electron microscope (Photo courtesy of LRI EM Unit)
Image: Prostate cancer cell image taken using a scanning electron microscope (Photo courtesy of LRI EM Unit)

Prostate cancer ranks as one of the most common cancers affecting men, and while it accounts for a significant number of male cancer fatalities, many men live with it rather than die from it. Understanding when to avoid unnecessary treatments is crucial, as it can prevent side effects like incontinence and impotence. Now, new research has identified two distinct subtypes of prostate cancer, referred to as evotypes. This discovery could lead to major advancements in the diagnosis and treatment of prostate cancer.

This discovery was made by an international consortium, called The Pan Prostate Cancer Group, which involved researchers from the University of Oxford (Oxford, UK), who used artificial intelligence (AI) to make new discoveries about the evolution of prostate cancer. Cancer development, like human evolution, can be traced and studied through its evolutionary history. By examining the cancer’s evolutionary tree, valuable insights about the disease can be gained, potentially aiding in the development of new treatments. The research involved an analysis of the DNA of prostate cancer samples from 159 patients through whole genome sequencing, a comprehensive method of examining an individual’s entire genetic material.

The team employed neural networks, an advanced AI technique, to compare the DNA of these samples. This analysis revealed two distinct cancer categories among the patients. These groups were further confirmed using two other mathematical methods applied to different data aspects. Moreover, this finding was corroborated in separate datasets from Canada and Australia. The researchers synthesized all this data to create an evolutionary tree depicting the development of the two prostate cancer subtypes, leading to the identification of two unique evotypes. Building on this discovery, the research team aims to develop a genetic test. This test, in conjunction with traditional staging and grading, could provide a more accurate prognosis for individual patients, enabling personalized treatment decisions. This innovation marks a significant leap forward in the field of prostate cancer research and treatment.

“Our research demonstrates that prostate tumors evolve along multiple pathways, leading to two distinct disease types,” said lead researcher Dr. Dan Woodcock, of the Nuffield Department of Surgical Sciences at the University of Oxford. “This understanding is pivotal as it allows us to classify tumors based on how the cancer evolves rather than solely on individual gene mutations or expression patterns.”

“This study is really important because until now, we thought that prostate cancer was just one type of disease. But it is only now, with advancements in artificial intelligence, that we have been able to show that there are actually two different subtypes at play,” said Professor Colin Cooper, from UEA’s Norwich Medical School. “We hope that the findings will not only save lives through better diagnosis and tailored treatments in the future, but they may help researchers working in other cancer fields better understand other types of cancer too.”

Related Links:
University of Oxford

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultrasonic Cleaner
UC 300 Series
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.